Crossmark

Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study

Crossref DOI link: https://doi.org/10.1007/s00125-018-4727-7

Published Online: 2018-09-19

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Fraty, Mathilde

Velho, Gilberto

Gand, Elise

Fumeron, Fréderic

Ragot, Stéphanie

Sosner, Philippe

Mohammedi, Kamel

Gellen, Barnabas

Saulnier, Pierre-Jean

Halimi, Jean-Michel

Montaigne, David

Ducrocq, Grégory

Rehman, Michaela

Marre, Michel

Roussel, Ronan

Hadjadj, Samy
License Information

Text and Data Mining valid from 2018-09-19
More Information

Article History

Received: 22 February 2018

Accepted: 3 August 2018

First Online: 19 September 2018

Duality of interest

: Plasma MR-proADM measurement was performed by Thermo Fisher Scientific (Hennigsdorf, Germany), in anonymised tubes, by personnel blinded to characteristics and outcomes of participants. No other potential duality of interest relevant to this article was reported.